(b)

Ms. Jane Axelad, Associate Director for Policy Center for Drug Evaluation and Research Food and Drug Administration Woodmont Building, Room 6027 Rockville, Maryland 20852

Dear Ms. Axelrad.

As you may recall, I presented some material pertaining to the use of DMPS (dimercapto propane sulfonate) to the Pharmacy Compounding Advisory Committee on July 13, 2000. After my presentation, there was some indication that no MedWatch reports had been received regarding this drug.

I thought that I had filed a MedWatch report on August 14, 1998. However, it seems that the report taken from me by FDA investigator Joseph Despins was actually an investigative report which he subsequently filed with Dr. Tony Carreras of the Division of Scientific Investigations. My understanding is that the subsequent investigation was dropped after it was discovered that DMPS was nominated for the Bulk Drug List.

I have today, therefore, filed a MedWatch report regarding my experience with this drug. Because there was some discussion that the MedWatch reporting system is not equipped for handling reports of adverse events for unapproved drugs, I am sending a copy to you to ensure that it is officially recorded.

I hope that the FDA is reviewing the appropriateness of this drug for inclusion on the Bulk Drug List. If I can be of assistance in any way, please do not hesitate to contact me. Thank you for your time and attention to this important maner.

Sincerely,

C14

98D-0272

For VOLUNTARY reporting by health professionals of adverse events and product problems

Form Appro	अ)। हाम क्षेत्र हा राष्ट्रीय क्षेत्र क्षेत्र होता है। स्थाप क्षेत्र के क्षेत्रकारकार्थ क्षेत्रकार होता होता
FDA USS ONLY	AND DESCRIPTION OF PERSON
Trage one	
endrigutus &	
	•

A Patient informati	of	
A. Patient information	C. Suspect medication(s)	
devent: LO	1. Name (the labeled strength & mfr/labeler, if known)	
or! If smale ()	"Dimercapto propone suffe	mate 250mg.
In confidence of birth;	142	ACCING.
B. Adverse event or product problem 1. Adverse event and/or Product problem (a.g. defendant)		ten (If unknown, give duration)
Dutcomes ambuted to adverse event	#1 M- 250m9 #1 2-2	7-98
(check all that apply) disability	#2 #2	
death congenital anomaly	4. Diagnosis for use (indication)	5. Event absted after use
(molteyhi) Traquired intervention to prevent	" hypothyroidism	Mobberg of dose Lagricus
permanent impairment/damage	MEDINATIONS	#1 Dyes Pro Dagger
hospitalization - Initial or prolonged other:	12	
3. Date of 9-37 90 4. Date of 9-17 00	6. Let # (if known) 7. Exp. date (if known)	#2 jyes ric doesn'
(modesyly) A A - 18 Unit report - 1 - OO	#1 #1	8. Event reappeared after
5. Describe event or problem	#2 #2	reintroduction
Consulted physician for mild hypo-	9. NDC \$ (for product problems only)	#1 yes no doesn'
thyroidism. He injected me with 250 mg		#2 has no doesn't
of OMPS (dimercapto propane sulfonati) as	10. Concomitant medical products and therapy dates (e	
_ - - - - - - - - -	I more than the second of the	TOOSE LESIMBUL OLENGUI)
part of a "DMPS challenge" test to prove		
affecting my thyroid. From this thecetion	D. Suspect medical device	
I suffered disabling fatigue, rausea,	1. Brand name	
De la		
Ediarrhea, stomach pain, headaches.	2. Type of device	
cognitive impairment, severe depression,	3. Manufecturer name & address	4. Operator of device
Ecognitive impairment, severe depression,		
		lay user/pational
It took over a year to become "normal"		other.
again, but I am still not back to the		
again, our i am stitution of the		
hearth I had prior to this injection.	6.	5. Expiration date (montage)
6. Relavant testalishoratory data, including dates	enodel #	
dates	Cartalog #	7. If implanted, give date
	(Mykiniyam)	
	entrial &	
	lox 8	8. If explained, give date
	Other #	(Michillay/lge)
	B. Device available for evaluation? (Co not sand	- FDA
	yes no refurned to mainufactur	
		The state of the s
7. Other reinvary bigraps legisdly	10. Concemberé medical products and therapy dates (exc	uge tradiment of event)
 Other relevant history, including pre-sisting medical conditions (e.g., allorgies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfurction, etc.) 		
Had been dinamend with any		
The Real Maritosia with asymptomatic	E Reporter (see confidentiality section (II II II II
hypothyraidism and was taking -05mg		1213,07
Had been diagnosed with asymptometic hypothyroidism and was taking .05mg		1
synthmid.)
J		1
	-	
Mail to: MEDWATCH OF FAX to: 5600 Flahers Lane 1-600-FDA-0178	D yes B' ro	
Rockville, MD 20632-9787	5 If you do WOT went your identity disclosed to	User facility
FDA Form 1889 Submission of a raport does not constitute an admission	THE COMPLETE OF PLACE AN " X " in skile how []	distributor
interest of the constitute at a constitute at	Mill madical paragraph of the mandates carry the	